Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Rexahn Pharmaceuticals stock

Own Rexahn Pharmaceuticals stock in just a few minutes.

Rexahn Pharmaceuticals, Inc is a biotechnology business based in the US. Rexahn Pharmaceuticals shares (REXN) are listed on the NASDAQ and all prices are listed in US Dollars. Rexahn Pharmaceuticals employs 5 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Rexahn Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – REXN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Rexahn Pharmaceuticals share price

Use our graph to track the performance of REXN stocks over time.

Rexahn Pharmaceuticals shares at a glance

Information last updated 2021-01-23.
52-week range$1.72 - $14.80
50-day moving average $7.20
200-day moving average $9.51
Wall St. target price$3.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.83

Buy Rexahn Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Rexahn Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rexahn Pharmaceuticals financials

Revenue TTM $1.2 million
Gross profit TTM $0
Return on assets TTM -33.73%
Return on equity TTM 0%
Profit margin 0%
Book value $2.93
Market capitalisation $2 million

TTM: trailing 12 months

Shorting Rexahn Pharmaceuticals shares

There are currently 13,595 Rexahn Pharmaceuticals shares held short by investors – that's known as Rexahn Pharmaceuticals's "short interest". This figure is 358.8% up from 2,963 last month.

There are a few different ways that this level of interest in shorting Rexahn Pharmaceuticals shares can be evaluated.

Rexahn Pharmaceuticals's "short interest ratio" (SIR)

Rexahn Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rexahn Pharmaceuticals shares currently shorted divided by the average quantity of Rexahn Pharmaceuticals shares traded daily (recently around 271900). Rexahn Pharmaceuticals's SIR currently stands at 0.05. In other words for every 100,000 Rexahn Pharmaceuticals shares traded daily on the market, roughly 50 shares are currently held short.

However Rexahn Pharmaceuticals's short interest can also be evaluated against the total number of Rexahn Pharmaceuticals shares, or, against the total number of tradable Rexahn Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rexahn Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Rexahn Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0008% of the tradable shares (for every 100,000 tradable Rexahn Pharmaceuticals shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Rexahn Pharmaceuticals.

Find out more about how you can short Rexahn Pharmaceuticals stock.

Rexahn Pharmaceuticals share dividends

We're not expecting Rexahn Pharmaceuticals to pay a dividend over the next 12 months.

Have Rexahn Pharmaceuticals's shares ever split?

Rexahn Pharmaceuticals's shares were split on a 1:12 basis on 11 April 2019. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rexahn Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Rexahn Pharmaceuticals shares which in turn could have impacted Rexahn Pharmaceuticals's share price.

Rexahn Pharmaceuticals share price volatility

Over the last 12 months, Rexahn Pharmaceuticals's shares have ranged in value from as little as $1.72 up to $14.8. A popular way to gauge a stock's volatility is its "beta".

REXN.US volatility(beta: 0.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rexahn Pharmaceuticals's is 0.973. This would suggest that Rexahn Pharmaceuticals's shares are less volatile than average (for this exchange).

Rexahn Pharmaceuticals overview

As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc. , in a reverse merger transaction. Rexahn Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site